Clinical Research Directory

Inclusion Criteria: * Adults aged 18-65 at the time of enrollment. * Generally healthy * BMI 18.5 - 35.0kg/m2 * Willing and able to provide informed consent. * Willing to consume one PeptiSleep or placebo capsule daily for 6 weeks. * Willing to wear a sleep tracker continuously throughout the study period. * Willing to complete all scheduled surveys and cognitive assessments on Days 0, 1, 2, and 3, at biweekly check-ins (Week 2 and Week 4), and at End-of-Study (Day 42). * Willing to sync their wearable device data through the Reputable Health app and complete daily check-ins for compliance assessment * Agree not to change current diet and/or exercise frequency or intensity during entire enrolment period. * Agree to maintain a stable lifestyle and medication routines for at least 4 weeks prior to enrollment * Agree not to use other medicines or supplements for sleep, stress, depression, or anxiety other than the test product during enrolment period. * Agree to refrain from participation in another clinical trial during enrolment period. * Agree to comply with Creyos digital platform data usage and privacy policy Exclusion Criteria: * Are currently pregnant, breastfeeding, or planning pregnancy during the study period. * Are using prescription or over-the-counter sleep medications (e.g., zolpidem, melatonin \>5 mg, benzodiazepines, CBD or antihistamines used for sleep, stress, depression, or anxiety within 4-weeks prior to enrolment. * Have a current diagnosis of a chronic medical condition or illness (e.g., uncontrolled thyroid disease, diabetes, cardiovascular disease, major depressive disorder, or anxiety disorder requiring ongoing pharmacologic treatment) or a chronic sleep disorder, insomnia, restless leg syndrome, sleep apnoea. * Are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 4-weeks and any other sleep clinical trial during the past 3 months. * Have a known allergy or sensitivity to any component of the investigational or placebo product * Are shift workers or have highly irregular sleep/wake schedules that could confound study outcomes. * Are unable or unwilling to comply with daily product use, wearable requirements, or survey/assessment completion. * Have with significant non-wear time of their Oura device exceeding a 48- hour period * Are using medications which induce CYP3A4 such as phenobarbital, phenytoin, rifampicin, St. John's Wort, and glucocorticoids. * Are using prescription or OTC medications or supplements for sleep, stress, depression, or anxiety including CBD within one month prior to enrolment. * Are using aromatherapy to help manage sleep, stress, depression, or anxiety within 4-weeks prior to enrolment. * Are using a digital device (besides Oura) to help monitor or manage sleep during the study period. * Have a current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years. * Have been diagnosed with or have consistent gastrointestinal issues that disrupt sleep. * Have a history of renal function impairment * Have with COPD or a chronic breathing disorder * Are active smokers, nicotine use or drug (prescription or illegal substances) abuse. * Have a chronic past and/or current alcohol use (\>14 alcoholic drinks week) * Are regularly taking stimulants (e.g., coffee, caffeine supplements, beverages containing caffeine) 5 hours before bed * Are regularly consuming more than 500mg of caffeine per day * Have any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.